Stereotactic Body Radiation Therapy for Re-irradiation of Persistent or Recurrent Non-Small Cell Lung Cancer
Creators
- 1. Department of Radiation Oncology, Centro di Riferimento Oncologico of Aviano, Pordenone (Italy)
- 2. Department of Epidemiology and Biostatistics, Centro di Riferimento Oncologico of Aviano, Pordenone (Italy)
- 3. Department of Medical Physics, Centro di Riferimento Oncologico of Aviano, Pordenone (Italy)
- 4. Department of Nuclear Medicine, Centro di Riferimento Oncologico of Aviano, Pordenone (Italy)
- 5. Department of Medical Oncology, Centro di Riferimento Oncologico of Aviano, Pordenone (Italy)
- 6. Department of Medical Oncology, Pordenone General Hospital, Aviano, Pordenone (Italy)
Description
Purpose: To retrospectively assess toxicity and outcome of re-irradiation with stereotactic body radiation therapy (SBRT) in patients with recurrent or persistent non-small cell lung cancer (NSCLC), who were previously treated with radical radiation therapy (50-60 Gy). The secondary endpoint was to investigate whether there are dosimetric parameter predictors of severe radiation toxicity. Methods and Materials: The analysis was conducted in 17 patients with "in-field" recurrent/persistent centrally located NSCLC, who underwent re-irradiation with SBRT. SBRT consisted of 30 Gy in 5 to 6 fractions; these prescriptions would be equivalent for the tumor to 37.5 to 40 Gy, bringing the total 2-Gy-per-fraction cumulative dose to 87 to 100 Gy, considering the primary radiation therapy treatment. Actuarial analyses and survival were calculated by the Kaplan-Meier method, and P values were estimated by the log-rank test, starting from the date of completion of SBRT. Dosimetric parameters from the subgroups with and without grade ≥3 pulmonary toxicity were compared using a 2-tailed Student t test. Results: The median follow-up was 18 months (range, 4-57 months). Only 2 patients had local failure, corresponding to a local control rate of 86% at 1 year. The Kaplan-Meier estimates of overall survival (OS) rates at 1 and 2 years were 59% and 29%, respectively; the median OS was 19 months. Four patients (23%) experienced grade 3 radiation pneumonitis, and 1 patient developed fatal pneumonitis. One patient died of fatal hemoptysis 2 months after the completion of SBRT. Unexpectedly, heart maximum dose, D5 (minimum dose to at least 5% of the heart volume), and D10 were correlated with risk of radiation pneumonitis (P<.05). Conclusions: Re-irradiation with SBRT for recurrent/persistent centrally located NSCLC achieves excellent results in terms of local control. However, the high rate of severe toxicity reported in our study is of concern
Availability note (English)
Available from http://dx.doi.org/10.1016/j.ijrobp.2014.01.012Additional details
Identifiers
- DOI
- 10.1016/j.ijrobp.2014.01.012;
- PII
- S0360-3016(14)00070-4;
Publishing Information
- Journal Title
- International Journal of Radiation Oncology, Biology and Physics
- Journal Volume
- 88
- Journal Issue
- 5
- Journal Page Range
- p. 1114-1119
- ISSN
- 0360-3016
- CODEN
- IOBPD3
INIS
- Country of Publication
- United States
- Country of Input or Organization
- International Atomic Energy Agency (IAEA)
- INIS RN
- 46122418
- Subject category
- S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Descriptors DEI
- COMPARATIVE EVALUATIONS; HAZARDS; HEART; LUNGS; NEOPLASMS; PATIENTS; PNEUMONITIS; RADIOTHERAPY; TOXICITY
- Descriptors DEC
- BODY; CARDIOVASCULAR SYSTEM; DISEASES; EVALUATION; MEDICINE; NUCLEAR MEDICINE; ORGANS; RADIOLOGY; RESPIRATORY SYSTEM; THERAPY
Optional Information
- Copyright
- Copyright (c) 2014 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.